Avidity Biosciences Inc
NASDAQ:RNA

  • LAST PRICE
    29.5100
  • TODAY'S CHANGE (%)
    0.6000 (2.0754%)
  • Bid / Lots
    28.7500/ 5
  • Ask / Lots
    29.5100/ 1
  • Open / Previous Close
    29.2900 / 28.9100
  • Day Range
    28.4000
    30.5400
  • 52 Week Range
    4.8250
    30.5400
  • Volume
    1,680,704

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 14 hours ago by PR Newswire
      Companies Mentioned: RNA

      Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases. 

    • 14 hours ago by Dow Jones
      Companies Mentioned: RNA

      Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

      PR Newswire

      SAN DIEGO, May 15, 2024

      SAN DIEGO, May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs(TM)), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases.

    • 14 hours ago by Dow Jones
      Companies Mentioned: RNA

      Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors

      PR Newswire

      SAN DIEGO, May 15, 2024

      SAN DIEGO, May 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs(TM)), today announced the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors. Ms. Skerjanec brings nearly three decades of global experience in the pharmaceutical industry with a strong track record in developing and launching therapies, as well as shaping corporate strategy to deliver transformative treatments to people living with serious diseases.

  • Yesterday

  • May 10, 2024

Peers Headlines